Which weight-loss pills are on the Malaysian register?
"Weight-loss pill" covers several different medicines, and each has its own status. A medicine is registered in Malaysia when it has a MAL number on the register kept by the National Pharmaceutical Regulatory Agency (NPRA), called QUEST3+. On 6 November 2026 the register's product search, run by active ingredient, listed these. The leaflet column quotes what each product's own leaflet or insert on the register says it is for.
| Medicine | On the register, 6 Nov 2026 | What the leaflet or insert says |
|---|---|---|
| Orlistat | 2 capsule products, including Xenical (MAL05032548ACRZ) | Xenical's leaflet (Malay) says it is used to treat obesity together with a low-calorie diet |
| Phentermine | 3 products: Duromine capsules (two strengths, MAL14035017ACRZ and MAL14035007ACRZ) and a phentermine tablet from a Malaysian holder (MAL16105033AZ) | Duromine's leaflet says it is used to reduce body weight in obese or overweight patients, within an overall weight management plan, and is only available with a doctor's prescription. The tablet's leaflet was not read |
| Naltrexone with bupropion | 1 product, Contrave prolonged-release tablet (MAL22096003ACRZ) | Used in obese or overweight adults to manage weight, together with a reduced calorie diet and physical exercise |
| Oral semaglutide | Rybelsus tablets (three entries, MAL22056044AZ, MAL22056045AZ and MAL22056046AZ); no tablet for weight | The package insert covers type 2 diabetes in adults |
| Orforglipron | No result for the ingredient or for the name Foundayo | Not applicable |
The register's results list shows the product name, registration number and holder, and does not print a status field, so "listed" is as far as this article goes. The register itself says its results apply only on the date and time of the search and that status can change. It is a snapshot, and it is worth running again before you act on it. Products sold as supplements or traditional medicines carry other MAL categories and are not covered here.
Is the Wegovy pill in Malaysia yet?
Not on the register. The Wegovy pill is once-daily oral semaglutide 25 mg. Novo Nordisk announced on 22 December 2025 that the US Food and Drug Administration had approved it to reduce excess body weight and maintain weight reduction long term, and to reduce the risk of major adverse cardiovascular events. That is a United States approval and says nothing by itself about Malaysia.
The Wegovy injection reached Malaysia first. Malay Mail reported on 15 January 2026 that Wegovy was "now officially available" here, as "a once-weekly injectable medication". A search of the register for semaglutide on 6 November 2026 returned 15 products: 2 Ozempic pens, 3 Rybelsus tablets and 10 Wegovy products, every one of them a solution for injection in a pre-filled pen. A search for the name Wegovy returned the same 10 pens and nothing else.
So a tablet offered in Malaysia as "Wegovy tablets", "the Wegovy pill" or "Ozempic pills" matches no registered product as the register stood that day. Ozempic is an injection pen, and the one semaglutide tablet on the register is Rybelsus. The sources cited here give no Malaysian launch date for the Wegovy pill, and this article does not guess one.
Is orforglipron, sold as Foundayo, registered here?
Orforglipron is a different medicine from semaglutide, made by Eli Lilly. Lilly announced on 1 April 2026 that the US FDA had approved Foundayo (orforglipron) for adults with obesity, or overweight with weight-related medical problems, and the Associated Press reported the approval the same day. On 6 November 2026 the NPRA register returned "No results found" for the active ingredient orforglipron and for the name Foundayo.
A medicine can be approved in one country and not yet registered in another, because each regulator reviews its own application. Until a product has a MAL number on the register, anything sold here under its name cannot be a registered product.
Is the Wegovy pill the same semaglutide as the Wegovy injection?
Novo Nordisk's own release describes both products as semaglutide: the pill as a semaglutide tablet taken once daily, the injection as semaglutide injectable given once weekly. The active ingredient has the same name. The products are separate, each with its own approval, label and registration, which is why Malaysia's ten Wegovy entries are all pens and say nothing about a tablet.
This article does not compare how well the two work, because the sources cited here do not settle that for Malaysian patients. The article on how the GLP-1 medicines differ sets out the injections and Rybelsus in more detail.
What separates a GLP-1 pill from a GLP-1 injection?
The sources cited here support a few plain differences. The route: one is swallowed, the other is injected. The schedule: Novo describes the pill as once daily and the injection as once weekly. The paperwork: each is a separate product with its own label. In Malaysia the register shows GLP-1 injections, such as semaglutide and tirzepatide pens, and a single GLP-1 tablet, Rybelsus, with a diabetes indication.
Which of them suits a person, if either does, depends on health history, other medicines and goals, and is decided at an assessment. These are prescription medicines. The legal route to GLP-1 medicines in Malaysia explains why the prescription matters.
What about phentermine, orlistat and naltrexone with bupropion?
All three have registered products. For phentermine, this article says only what the register and the Duromine leaflet say: that it is used to reduce body weight in obese or overweight patients as part of an overall weight management plan with a medically controlled diet and exercise, and that it is only available with a doctor's prescription. It adds nothing about who it suits or how it is used.
Orlistat's leaflet says it is used to treat obesity together with a low-calorie diet, and that it works by stopping some of the fat in food from being absorbed. The Contrave leaflet describes naltrexone with bupropion as acting on areas of the brain involved in controlling food intake and energy use. Whether any of them is right for you is a question for a doctor who has your history. None is a substitute for that conversation, and none is ranked above another here.
How do I check a weight-loss pill before I buy it?
Start with the label. The Ministry of Health says a valid registration number begins with "MAL", is followed by 8 digits and ends with a letter that shows the registration category. Registered medicines also carry a Meditag hologram label, and the Ministry advises checking the hologram with a pharmacist. Then search the number, or the product name, on the NPRA register. The product-name search wants at least five characters.
Compare what comes back with what is in your hand: the name, the holder, the active ingredient. A pack that says "approved by KKM" without a MAL number that matches the register has not shown you a registration. The Ministry's FAQ is plain on the point: a medicine without a MAL number is an unregistered product and may not be sold or advertised in Malaysia.
Pens and tablets sold online raise the same questions. The article on checking a pen before you inject covers counterfeits, and the one on Reta and Mounjaro shows what an unregistered product looks like in practice.
What does The Retreat Clinic offer?
The Retreat Clinic is a doctor-led aesthetic clinic in Setia Alam, Shah Alam. The clinic's weight management page describes a pathway that begins with a medical assessment: a history, an examination and usually blood tests. Where the assessment supports it, treatment may include prescription medicines, which the page names as the GLP-1 receptor agonists and the newer dual agonists, with follow-up for as long as treatment continues. The page says that nothing is prescribed at the assessment itself, and that Dr Ong declines to prescribe where the medicine does not fit.
The page does not list any weight-loss tablet, and this article does not say that the clinic offers one. It names the medicines above because people search for them and the register is public.
